

(R)-N-[5-Methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydronaphthyl]-4-morpholinobenzamide
CONTROL
1.0µM S2/S1=258
0.1µM S2/S1=205
0.01µM S2/S1=144
% OF BASAL RELEASE
FRACTIONS
S1
S2
0
0.5
1
1.5
2
2.5
3
3.5
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Fig. 1

Fig. 2

5-HT turnover *Ex Vivo* - combination of a h5-HT_{1B} antagonist (A) with a 5-HT_{1A} antagonist (B)

